IGF1R and neoplasm: Though, multivariable analysis suggested that the reduced recurrence-risk among normal-weight tamoxifen-treated patients with ER+ tumors with known IGF1R tumor expression (n = 254) could not be explained by decreased IGF1R tumor expression (adjusted Ptrend = 0.97).